Pharmaceutical Marketing and The N.J. Consumer Fraud Act
Florham Park partner Ken Wilbur wrote an article for the New Jersey Law Journal titled, “Pharmaceutical Marketing and The N.J. Consumer Fraud Act.”
Ken notes that while consumer protection statutes, if applied without consideration of interests other than consumer protection, can cross the dividing line between effective and oppressive government action. His article discusses safeguards in the New Jersey Consumer Fraud Act that should prevent the Act from being used, like similar statutes in other states, to penalize pharmaceutical marketing for its mere potential to be misunderstood. It also explains how the Supreme Court’s recent decision in United States v. Alvarez should also preclude application of the Act in this manner.
The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.
Meet the Authors
